Wall Street brokerages forecast that Hologic, Inc. (NASDAQ:HOLX) will announce $779.91 million in sales for the current quarter, Zacks reports. Six analysts have made estimates for Hologic’s earnings, with estimates ranging from $777.70 million to $783.70 million. Hologic posted sales of $715.40 million in the same quarter last year, which suggests a positive year over year growth rate of 9%. The firm is scheduled to announce its next quarterly earnings report on Wednesday, May 9th.
On average, analysts expect that Hologic will report full year sales of $779.91 million for the current financial year, with estimates ranging from $3.23 billion to $3.28 billion. For the next fiscal year, analysts forecast that the firm will report sales of $3.40 billion per share, with estimates ranging from $3.37 billion to $3.43 billion. Zacks Investment Research’s sales calculations are a mean average based on a survey of research analysts that follow Hologic.
Hologic (NASDAQ:HOLX) last posted its quarterly earnings results on Thursday, February 8th. The medical equipment provider reported $0.55 EPS for the quarter, topping the Zacks’ consensus estimate of $0.50 by $0.05. Hologic had a return on equity of 20.07% and a net margin of 34.53%. The company had revenue of $791.10 million for the quarter, compared to analysts’ expectations of $785.80 million. During the same period in the previous year, the firm earned $0.52 EPS. The firm’s revenue was up 7.7% compared to the same quarter last year.
Hologic (HOLX) traded down $0.03 during midday trading on Friday, reaching $37.81. The company had a trading volume of 2,949,347 shares, compared to its average volume of 2,640,376. The company has a current ratio of 1.25, a quick ratio of 0.98 and a debt-to-equity ratio of 0.87. Hologic has a one year low of $35.33 and a one year high of $46.80. The stock has a market cap of $10,635.31, a PE ratio of 9.98, a PEG ratio of 1.73 and a beta of 0.84.
In related news, Director Namal Nawana bought 6,600 shares of the business’s stock in a transaction dated Tuesday, February 13th. The shares were purchased at an average price of $37.88 per share, with a total value of $250,008.00. Following the transaction, the director now owns 6,954 shares in the company, valued at approximately $263,417.52. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Charles J. Dockendorff bought 13,000 shares of the business’s stock in a transaction dated Thursday, March 15th. The shares were bought at an average cost of $38.80 per share, for a total transaction of $504,400.00. The disclosure for this purchase can be found here. 0.88% of the stock is owned by corporate insiders.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Grove Bank & Trust increased its position in shares of Hologic by 115.8% during the 3rd quarter. Grove Bank & Trust now owns 2,860 shares of the medical equipment provider’s stock valued at $105,000 after purchasing an additional 1,535 shares during the last quarter. NuWave Investment Management LLC bought a new position in shares of Hologic during the 4th quarter valued at approximately $199,000. Fiduciary Trust Co. bought a new position in shares of Hologic during the 4th quarter valued at approximately $208,000. Advisor Partners LLC bought a new position in shares of Hologic during the 4th quarter valued at approximately $209,000. Finally, MPS Loria Financial Planners LLC bought a new position in shares of Hologic during the 4th quarter valued at approximately $214,000. 97.56% of the stock is currently owned by hedge funds and other institutional investors.
Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.